His aim is to reduce the prevalence of blindness using translational research to develop effective new treatments for retinal vascular and neurodegenerative diseases. He collaborates widely in multidisciplinary research programmes to develop new molecular and cellular therapies. His own programme of research extends from the laboratory investigation of mechanisms of retinal disease in experimental models, through preclinical development of novel therapies, to clinical trials of new medical and surgical interventions. In 2007 he performed the World's first gene therapy for inherited blindness and in 2012 Europe's first stem cell transplantation for macular degeneration.